Stryker Corporation
SYK
$325.70
-6.42%
Stryker Corporation is a leading medical device company that designs, manufactures, and markets a broad portfolio of orthopedic implants, surgical equipment, neurotechnology, and hospital supplies. As one of the top three players in reconstructive orthopedic implants and the market leader in operating room equipment, Stryker holds a strong competitive position in the global medical devices industry. The current investor narrative centers on the company's growth trajectory amid a challenging macro environment, with recent acquisitions like Amplitude Vascular Systems aimed at expanding its peripheral vascular portfolio. Additionally, debates around margin sustainability and the impact of elective procedure volumes on orthopedic sales are key focal points for the stock.…
SYK
Stryker Corporation
$325.70
Related headlines
Investment Opinion: Should I buy SYK Today?
Rating: Hold. Stryker is a high-quality medical device company with a strong competitive position, but current valuation and margin headwinds limit near-term upside. The consensus analyst rating is Buy with an average target of $386.52, implying 17% upside, but the stock's technical downtrend and fundamental deceleration warrant caution.
Supporting Evidence: The forward P/E of 19.75x is reasonable, but the trailing P/E of 41.4x is elevated. Revenue growth of 2.63% YoY is below the sector average, and operating margin compressed from 27.35% to 15.55% in the latest quarter. Free cash flow of $4.571B is strong, providing a 3.4% yield. The PEG ratio of 5.16x suggests growth expectations are fully priced in. Compared to industry peers, Stryker's valuation is at a premium, but its market leadership justifies some premium.
Risks & Conditions: The biggest risks are margin compression, revenue deceleration, and multiple contraction. This Hold would upgrade to Buy if the forward P/E compresses below 17x or if revenue growth accelerates above 5% YoY. It would downgrade to Sell if operating margins fall below 14% or if the stock breaks below the 52-week low of $281.00. Overall, SYK appears fairly valued relative to its growth prospects, with limited upside in the near term.
Sign up to view all
SYK 12-Month Price Forecast
Stryker is a high-quality company facing near-term headwinds from margin compression and slowing growth. The forward P/E of 19.75x is attractive, but the trailing P/E of 41.4x and PEG of 5.16x suggest limited upside unless margins recover. The 12-month outlook is neutral with a base case of trading near the average target. An upgrade to bullish would require evidence of margin stabilization and revenue acceleration, while a downgrade to bearish would follow further margin deterioration or a break below $315.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $387.04 and implied upside of +18.8% versus the current price.
Average Target
$387.04
0 analysts
Implied Upside
+18.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$315 - $465
Analyst target range
Stryker is covered by 25 analysts, with a consensus recommendation of 'Buy' (mean rating 1.63 on a 1-5 scale, where 1 is Strong Buy). The average target price is $386.52, implying approximately 17.0% upside from the current price of $330.25. The distribution leans bullish, with recent upgrades from BMO Capital (to Outperform) and reaffirmations from Evercore ISI, Leerink Partners, and others. The target range spans from $315.00 (low) to $465.00 (high). The high target of $465 assumes strong execution on growth initiatives, margin expansion, and multiple expansion, while the low target of $315 reflects risks such as slower procedure volumes, margin compression, or competitive pressures. The wide spread ($150) indicates significant uncertainty among analysts, but the overall bullish consensus suggests confidence in Stryker's long-term prospects. Recent ratings actions have been predominantly positive, with no downgrades noted, reinforcing the constructive sentiment.
Drowning in data?
Find the real signal!
Bulls vs Bears: SYK Investment Factors
Stryker presents a mixed picture: strong analyst consensus, robust free cash flow, and a reasonable forward P/E support the bull case, while decelerating revenue growth, margin compression, and a high trailing P/E fuel bearish concerns. The single most important tension is whether the company can deliver the earnings growth implied by the forward P/E (19.75x) despite margin headwinds and slowing top-line expansion. Currently, the bull case has slightly stronger evidence given the 17% upside to analyst targets and the company's competitive moat, but execution risk is high.
Bullish
- Strong Buy Consensus with 17% Upside: 25 analysts rate SYK a Buy (mean 1.63/5), with an average target of $386.52, implying 17.0% upside from $330.25. Recent upgrades from BMO Capital and reaffirmations from Evercore ISI reinforce positive sentiment.
- Healthy Free Cash Flow Generation: TTM free cash flow is $4.571 billion, representing a 3.4% yield on market cap. This provides ample capacity for acquisitions (e.g., Amplitude Vascular Systems), R&D ($413M in Q1 2026), and dividends.
- Leading Market Positions in Orthopedics and OR Equipment: Stryker is one of the top three in reconstructive orthopedic implants and the market leader in operating room equipment. This competitive moat supports stable demand and pricing power.
- Forward P/E at Reasonable 19.75x: The forward P/E of 19.75x is near the lower end of its 5-year range (24x-77x trailing), suggesting the market is pricing in a significant earnings rebound. If achieved, the stock could re-rate higher.
Bearish
- Revenue Growth Decelerating to 2.6% YoY: Q1 2026 revenue grew only 2.63% YoY to $6.02B, below historical averages. This deceleration signals mature markets and potential headwinds from elective procedure normalization.
- Operating Margin Compression from 27.3% to 15.6%: Operating margin fell sharply from 27.35% in Q4 2025 to 15.55% in Q1 2026, driven by higher R&D ($413M) and SG&A ($2.281B). Sustained margin pressure could erode earnings.
- Elevated Trailing P/E of 41.4x: The trailing P/E of 41.4x is above the broader market and implies high expectations. Any earnings miss could lead to multiple compression and downside.
- Stock in Sustained Downtrend, Down 16.7% in 1 Year: SYK has underperformed the S&P 500 by 33.2% over the past year, with a 1-year price change of -16.74%. Technical weakness may persist until fundamentals improve.
SYK Technical Analysis
Stryker's stock is in a sustained downtrend over the past year, with a 1-year price change of -16.74%, significantly underperforming the S&P 500's +16.47% gain. The current price of $330.25 sits at 48.5% of its 52-week range (low $281.00, high $404.14), indicating it is closer to the low end. This positioning suggests the stock is in a bearish phase, potentially offering a value opportunity if fundamentals support a recovery, but also risks further downside if negative momentum persists. Short-term momentum shows a mixed picture: the 1-month price change is +5.28%, while the 3-month change is only +0.84%, indicating a recent bounce but weak intermediate-term strength. The 1-month relative strength of +4.50% versus the S&P 500 suggests a short-term outperformance, but the 3-month relative strength of -2.66% confirms the broader downtrend. This divergence could signal a potential trend reversal if the recent rally sustains, or a temporary pullback within a larger bearish structure. The 52-week low of $281.00 provides key support, while resistance is at the 52-week high of $404.14. A breakout above $404 would signal a strong reversal, while a breakdown below $281 could accelerate selling. Stryker's beta of 0.778 indicates it is less volatile than the market, meaning it may not participate as strongly in broad market rallies but could also decline less during downturns, which is relevant for risk management.
Beta
—
—
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$397
Price range past year
Annual Return
-17.1%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +3.9% | +0.2% |
| 3m | +10.5% | +3.7% |
| 6m | -11.9% | +8.0% |
| 1y | -17.1% | +18.2% |
| ytd | -6.5% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue trajectory shows modest growth, with Q1 2026 revenue of $6.02 billion, up 2.63% year-over-year from $5.866 billion in Q1 2025. However, the multi-quarter trend reveals deceleration: Q4 2025 revenue was $7.171 billion (up from $6.436 billion in Q4 2024), while Q3 2025 revenue was $6.057 billion. The MedSurg segment contributed $3.207 billion and Orthopaedics $2.813 billion in Q1 2026, with both segments showing steady demand. The 2.63% YoY growth is below historical averages, suggesting a mature market and potential headwinds from procedure volume normalization. The company is profitable, with Q1 2026 net income of $745 million and a gross margin of 63.29%. However, margins have compressed: the gross margin declined from 65.22% in Q4 2025 to 63.29% in Q1 2026, and the operating margin fell from 27.35% to 15.55% over the same period, partly due to higher R&D spending ($413 million) and SG&A costs ($2.281 billion). The net margin of 12.38% in Q1 2026 is down from 14.68% in Q2 2025, indicating pressure on profitability. Stryker maintains a healthy balance sheet with a debt-to-equity ratio of 0.73 and a current ratio of 1.89, indicating adequate liquidity. Free cash flow (TTM) is $4.571 billion, providing ample capacity for internal growth and acquisitions. ROE stands at 14.48%, reflecting efficient capital use, while the free cash flow yield (FCF/market cap) is approximately 3.4%, suggesting moderate cash generation relative to valuation.
Quarterly Revenue
$6.0B
2026-03
Revenue YoY Growth
+2.6%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$4.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given Stryker's positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 41.40x, while the forward P/E is 19.75x, a significant gap that implies the market expects strong earnings growth in the coming year. This forward multiple suggests a PEG ratio of 5.16x, indicating that growth expectations are already priced in. Compared to the industry average (not provided), Stryker's trailing P/E of 41.4x appears elevated relative to the broader market, but the forward P/E of 19.75x is more reasonable. The EV/EBITDA multiple of 23.23x also suggests a premium valuation. Historically, Stryker's trailing P/E has ranged from around 24x to 77x over the past five years. The current 41.4x is near the middle of this range, but the forward P/E of 19.75x is near the lower end, indicating that the market is pricing in a significant earnings rebound. This could be justified by the company's strong competitive position and growth initiatives, but it also leaves little room for disappointment.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stryker's operating margin compressed from 27.35% in Q4 2025 to 15.55% in Q1 2026, a decline of nearly 12 percentage points, driven by higher R&D spending ($413M) and SG&A costs ($2.281B). Net margin also fell from 14.68% in Q2 2025 to 12.38% in Q1 2026. While the balance sheet is healthy (debt-to-equity 0.73, current ratio 1.89), the margin trajectory is concerning. Revenue growth of only 2.63% YoY in Q1 2026 is below historical norms, indicating that the company may be facing mature market dynamics and normalization of elective procedure volumes. Free cash flow of $4.571B is strong, but if margins continue to erode, cash generation could weaken.
Market & Competitive Risks: Stryker's trailing P/E of 41.4x is elevated relative to the broader market, making it vulnerable to valuation compression if growth disappoints. The stock has a beta of 0.778, indicating lower market correlation, but its 1-year relative strength of -33.2% versus the S&P 500 shows significant underperformance. Competitive pressures in orthopedics (e.g., from Zimmer Biomet, Johnson & Johnson) and surgical equipment could intensify. The recent acquisition of Amplitude Vascular Systems adds growth optionality but also integration risk. Regulatory headwinds in healthcare pricing and reimbursement could also impact margins.
Worst-Case Scenario: If revenue growth stalls below 2%, margins continue to compress, and the forward P/E re-rates to 15x (a discount to the market), the stock could fall to the 52-week low of $281.00, representing a 14.9% decline from the current price of $330.25. In a severe recession or adverse regulatory change, the stock could test the analyst low target of $315.00, a 4.6% downside. The maximum drawdown over the past year was -29.97%, suggesting a potential loss of up to 30% from peak to trough.
FAQ
The key risks are: 1) Margin compression – operating margin fell from 27.35% to 15.55% in one quarter, and if it continues, earnings could disappoint. 2) Revenue deceleration – growth of only 2.63% YoY is below historical averages, and any further slowdown could lead to multiple contraction. 3) Valuation risk – the trailing P/E of 41.4x leaves little room for error; an earnings miss could trigger a sharp sell-off. 4) Competitive and regulatory risks – competition from Zimmer Biomet and J&J, plus potential healthcare policy changes, could pressure margins. The most severe risk is a combination of margin compression and revenue deceleration, which could drive the stock to the 52-week low of $281.
The 12-month forecast for SYK is neutral to slightly bullish. The base case (50% probability) sees the stock trading near the average analyst target of $386.52, implying 17% upside, assuming revenue growth of 3-4% and stable margins. The bull case (25% probability) targets $465 (40.8% upside) if margins recover and growth accelerates. The bear case (25% probability) sees the stock falling to $315-$281 (4.6%-14.9% downside) if margins continue to compress and growth disappoints. The most likely scenario is the base case, with the key assumption being that operating margins stabilize around 18-20%.
Stryker's valuation is mixed. The trailing P/E of 41.4x is above the broader market and its own 5-year average, suggesting it is overvalued based on past earnings. However, the forward P/E of 19.75x is more reasonable and implies strong earnings growth expectations. The PEG ratio of 5.16x indicates that growth is fully priced in. Compared to the industry, SYK trades at a premium, but its market leadership in orthopedics and OR equipment justifies some premium. Overall, the stock appears fairly valued relative to its growth prospects, with limited upside in the near term.
SYK is a high-quality medical device company with a strong competitive position, but it is not a clear buy at current levels. The stock offers 17% upside to the average analyst target of $386.52, but the trailing P/E of 41.4x is elevated and revenue growth is decelerating at 2.63% YoY. The biggest downside risk is further margin compression, which could push the stock to the 52-week low of $281. For long-term investors with a 3-5 year horizon, SYK could be a good addition given its free cash flow generation and market leadership. However, for short-term traders, the technical downtrend and margin headwinds suggest waiting for a better entry point.
SYK is better suited for long-term investment due to its stable business model, strong free cash flow ($4.571B TTM), and market leadership. The stock has a beta of 0.778, indicating lower volatility than the market, and pays a dividend yield of 0.96%. Short-term trading is risky given the technical downtrend and margin headwinds. A minimum holding period of 3-5 years is recommended to allow the company to execute on its growth initiatives and for margins to recover. For long-term investors, the current price offers a reasonable entry point, but near-term volatility should be expected.